Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Ultra Nasdaq Biotech Proshares (BIB)

$70.77 2.66 (3.91%)

17:46 EDT BIB Stock Quote Delayed 30 Minutes

Volume:

Previous Close $70.77

Market Cap 495.39M

PE Ratio -

EPS -

Volume (Avg. Vol.) 424,600

Day's Range 66.28 - 70.96

52-Week Range 35.49 - 72.47

Dividend & Yield N/A (N/A)

BIB Stock Predictions, Articles, and Ultra Nasdaq Biotech Proshares News

From the Web

Roche Starts Study on Actemra with Gilead's Drug for Coronavirus

From Zacks Investment Research May 29, 2020

Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.

Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today

From The Motley Fool May 29, 2020

The development-stage biopharma is bouncing back from a recent stock dip.

What to watch today: Dow futures fall ahead of Trump's China news conference

From CNBC May 29, 2020

Dow futures fell Friday after President Trump knocked the wind out Thursday's solid gains on Wall Street when he said he would hold a news conference on China.

Coronavirus live updates: Russia sees most deaths in a day; FDA to face delays on clinical trials

From CNBC May 29, 2020

The coronavirus has infected more than 5.8 million people around the world as of Friday, killing at least 360,860 people.

Gilead not quite there with remdesivir nod in Europe (NASDAQ:GILD)

From Seeking Alpha May 29, 2020

In an update, the European Medicines Agency's advisory group CHMP states that it has started a rolling review of data on Gilead Sciences' (NASDAQ:GILD) remdesivir for COVID-19. It finished the first c

All eyes on ASCO (NASDAQ:AMGN)

From Seeking Alpha May 29, 2020

The highly-watched American Society of Clinical Oncology meeting pivots to a virtual format for the first time ever this year.While as many as 40K medical professionals and scientists typically attend